The ODD will offer clinical development and commercialisation benefits that will strengthen the drug programme
Faron Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its bexmarilimab for acute myeloid leukaemia (AML).
The ODD will offer clinical development and commercialisation benefits that will ultimately strengthen the drug programme.
